Oral Losartan After Limited Mandibulectomy for Treatment of Desmoid-Type Fibromatosis

Ear Nose Throat J. 2023 Feb;102(2):NP49-NP52. doi: 10.1177/0145561320987641. Epub 2021 Jan 25.

Abstract

Desmoid-type fibromatosis (DF) is a rare soft tissue lesion with an annual incidence of 2 to 4 per million population and peak incidence occurring at approximately 4.5 years of age. While benign, the tumor has a locally aggressive infiltrative growth pattern and a high rate of recurrence. Given the functional and aesthetic implications of excision and reconstruction in the facial skeleton, novel medical treatment options are highly desirable. We describe the case of a 3-year-old boy who presented with an enlarging, asymptomatic mass involving the left mandible. Biopsy revealed an immunohistochemical profile consistent with DF. Despite the high likelihood of recurrence, conservative, mandible-sparing en bloc resection and limited mandibulectomy were performed. Pathological and immunohistochemical analysis of the resection specimen revealed DF with grossly positive margins and elevated expression of angiotensin II type 1 receptor. Postoperative medical treatment with the angiotensin receptor blocker losartan was initiated. The patient remains medically stable and disease progression-free on repeat imaging at 20 months post-resection. We describe for the first time the successful use of the angiotensin blocker losartan following conservative surgery for management of DF.

Keywords: angiotensin-receptor type I; case report; desmoid; losartan; mandible.

Publication types

  • Case Reports

MeSH terms

  • Biopsy
  • Child, Preschool
  • Fibromatosis, Aggressive* / drug therapy
  • Fibromatosis, Aggressive* / pathology
  • Fibromatosis, Aggressive* / surgery
  • Humans
  • Losartan / therapeutic use
  • Male
  • Mandibular Osteotomy
  • Margins of Excision

Substances

  • Losartan